Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MELINTA THERAPEUTICS, INC. /NEW/MLNT · Entity 154249 | Director | June 11, 2019 | June 12, 2019 |
| SAB Biotherapeutics, Inc.SABS · Entity 5816 | Director | January 05, 2026 | January 07, 2026 |
| Vor Biopharma Inc.VOR · Entity 4763 | Director | July 07, 2026 | July 09, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MELINTA THERAPEUTICS, INC. /NEW/
Report date June 11, 2019 · Filed June 12, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Melinta Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 | Direct | 30,000 |
Reported balance
After 2019-06-11 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-06-11 · Grant · Acquired 30,000 · Balance 30,000 F1: The restricted stock units will vest on the day before the 2020 Annual Meeting of Shareholders, or approximately June 7, 2020, subject to continued service with the Issuer through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units will vest on the day before the 2020 Annual Meeting of Shareholders, or approximately June 7, 2020, subject to continued service with the Issuer through the applicable vesting date.
SAB Biotherapeutics, Inc.
Report date January 05, 2026 · Filed January 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.74 · Expires 2036-01-05 | Direct | 240,000 |
Reported balance
After 2026-01-05 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-01-05 · Grant · Acquired 240,000 · Balance 240,000 F1: Represents the inaugural grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in three equal annual installments on January 5, 2027, January 5, 2028 and January 5, 2029. F2: This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the inaugural grant to the Reporting Person as a member of the Board of Directors of the Issuer. Shares underlying the option vest in three equal annual installments on January 5, 2027, January 5, 2028 and January 5, 2029.
F2: This award was made pursuant to the Issuer's 2021 Omnibus Equity Incentive Plan, as amended.
Vor Biopharma Inc.
Report date July 07, 2026 · Filed July 09, 2026
This filing explicitly reported no securities owned.
Past disclosures · reporting ended (2)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Dova Pharmaceuticals Inc.
Report date November 12, 2019 · Filed November 12, 2019
Section 16 reporting ended · disclosed 2019-11-12. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2019-11-12 transaction · row 1
1 source rowRow 1 · 2019-11-12 · Disposition to issuer · Disposed 76,647 · Balance 0 F1: Disposed pursuant to an agreement and plan of merger by and between the Issuer, Swedish Orphan Biovitrum AB and Dragonfly Acquisition Corp. (the "Merger") in exchange for $27.50 per share of Issuer's common stock including any shares subject to each restricted stock unit on the effective date of the Merger, plus (ii) one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone. |
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $6.07 · Expires 2018-12-18 | Direct | 0 |
Reported balance
After 2019-11-12 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2019-11-12 · Disposition to issuer · Disposed 1,000,000 · Balance 0 F2: This option, which provided for vesting over a period of four years as follows: 25% of the total shares subject to the option shall vest on December 17, 2019, and 1/48th of total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, was accelerated and canceled in the Merger in exchange for a cash payment of $21,430,000.00, representing the difference between the exercise price of outstanding shares subject to the option and the market value of the underlying common stock on the effective date of the Merger ($27.50 per share). In addition, one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone was awarded to the Reporting Person for each outstanding share subject to the option. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed pursuant to an agreement and plan of merger by and between the Issuer, Swedish Orphan Biovitrum AB and Dragonfly Acquisition Corp. (the "Merger") in exchange for $27.50 per share of Issuer's common stock including any shares subject to each restricted stock unit on the effective date of the Merger, plus (ii) one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone.
F2: This option, which provided for vesting over a period of four years as follows: 25% of the total shares subject to the option shall vest on December 17, 2019, and 1/48th of total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, was accelerated and canceled in the Merger in exchange for a cash payment of $21,430,000.00, representing the difference between the exercise price of outstanding shares subject to the option and the market value of the underlying common stock on the effective date of the Merger ($27.50 per share). In addition, one non-transferable contingent value right per share, which represents the right to receive $1.50, without interest and subject to any withholding taxes, upon the achievement of a specified milestone was awarded to the Reporting Person for each outstanding share subject to the option.
Verona Pharma plc
Report date October 07, 2025 · Filed October 08, 2025
Section 16 reporting ended · disclosed 2025-10-08. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 0 |
Last balance in matching sequence
After 2025-10-07 transaction · row 3
Source-order balances reconcile. Account continuity and personal attribution are not independently verified.
3 source rowsRow 1 · 2025-10-07 · Disposition to issuer · Disposed 12,176,144 · Balance 0 F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F2: Represents Ordinary Shares of the Issuer acquired from the Reporting Person by means of a scheme of arrangement (the "Scheme of Arrangement") under Part 26 of the UK Companies Act 2006, pursuant to a transaction agreement, dated as of July 8, 2025 (the "Transaction Agreement"), by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent") and Vol Holdings LLC, a Delaware limited liability company and wholly owned subsidiary of Parent ("Bidco"). F3: At the effective time of the Scheme of Arrangement (the "Effective Time"), each holder of the Scheme Shares (as defined in the Scheme of Arrangement) became entitled to receive $13.375 in cash per Scheme Share, without interest and net of any applicable withholding taxes. Because each ADS represents a beneficial ownership interest in eight (8) Ordinary Shares of the Issuer, holders of ADSs as of the Effective Time became entitled to receive eight (8) times the foregoing cash amount, or $107 in cash, without interest and net of any applicable withholding taxes, per ADS (the "ADS Consideration"). F4: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. Row 2 · 2025-10-07 · Exercise / conversion · Acquired 3,285,280 · Balance 3,285,280 F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F4: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. F6: These performance-based restricted share unit awards (the "PRSUs") were earned upon the determination by the Board of Directors of the Issuer that certain performance metrics had been achieved. Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the PRSUs, unless agreed otherwise, became fully vested, and at the Effective Time, were automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such PRSU Award and (ii) the ADS Consideration. Row 3 · 2025-10-07 · Disposition to issuer · Disposed 3,285,280 · Balance 0 F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. F4: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. F6: These performance-based restricted share unit awards (the "PRSUs") were earned upon the determination by the Board of Directors of the Issuer that certain performance metrics had been achieved. Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the PRSUs, unless agreed otherwise, became fully vested, and at the Effective Time, were automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such PRSU Award and (ii) the ADS Consideration. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-10-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2025-10-07 · Exercise / conversion · Disposed 800,000 · Balance 0 F5: Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. F6: These performance-based restricted share unit awards (the "PRSUs") were earned upon the determination by the Board of Directors of the Issuer that certain performance metrics had been achieved. Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the PRSUs, unless agreed otherwise, became fully vested, and at the Effective Time, were automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such PRSU Award and (ii) the ADS Consideration. F4: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-10-07 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2025-10-07 · Exercise / conversion · Disposed 389,792 · Balance 0 F5: Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. F4: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-10-07 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2025-10-07 · Exercise / conversion · Disposed 445,536 · Balance 0 F5: Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. F4: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration. F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 1,649,952 |
Reported balance
After 2025-10-07 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2025-10-07 · Grant · Acquired 1,649,952 · Balance 1,649,952 F5: Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. F6: These performance-based restricted share unit awards (the "PRSUs") were earned upon the determination by the Board of Directors of the Issuer that certain performance metrics had been achieved. Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the PRSUs, unless agreed otherwise, became fully vested, and at the Effective Time, were automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such PRSU Award and (ii) the ADS Consideration. F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. |
| Restricted Share UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2025-10-07 transaction · row 8
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 8 · 2025-10-07 · Exercise / conversion · Disposed 1,649,952 · Balance 0 F5: Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date. F6: These performance-based restricted share unit awards (the "PRSUs") were earned upon the determination by the Board of Directors of the Issuer that certain performance metrics had been achieved. Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the PRSUs, unless agreed otherwise, became fully vested, and at the Effective Time, were automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such PRSU Award and (ii) the ADS Consideration. F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Reported securities are represented by American Depositary Shares ("ADSs"), each of which represents eight (8) Ordinary Shares of the Issuer.
F2: Represents Ordinary Shares of the Issuer acquired from the Reporting Person by means of a scheme of arrangement (the "Scheme of Arrangement") under Part 26 of the UK Companies Act 2006, pursuant to a transaction agreement, dated as of July 8, 2025 (the "Transaction Agreement"), by and among the Issuer, Merck Sharp & Dohme LLC, a New Jersey limited liability company ("Parent") and Vol Holdings LLC, a Delaware limited liability company and wholly owned subsidiary of Parent ("Bidco").
F3: At the effective time of the Scheme of Arrangement (the "Effective Time"), each holder of the Scheme Shares (as defined in the Scheme of Arrangement) became entitled to receive $13.375 in cash per Scheme Share, without interest and net of any applicable withholding taxes. Because each ADS represents a beneficial ownership interest in eight (8) Ordinary Shares of the Issuer, holders of ADSs as of the Effective Time became entitled to receive eight (8) times the foregoing cash amount, or $107 in cash, without interest and net of any applicable withholding taxes, per ADS (the "ADS Consideration").
F4: Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, each outstanding time-based restricted share unit award ("RSU Award"), unless agreed otherwise, became fully vested, and at the Effective Time, was automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such RSU Award and (ii) the ADS Consideration.
F5: Represents an award of RSUs covering ADSs, which is presented in terms of the equivalent number of Ordinary Shares underlying the ADSs. Each RSU represents a contingent right to receive one (1) ADS of the Issuer. Each ADS represents eight (8) Ordinary Shares of the Issuer. The RSUs have no expiration date.
F6: These performance-based restricted share unit awards (the "PRSUs") were earned upon the determination by the Board of Directors of the Issuer that certain performance metrics had been achieved. Pursuant to the terms of the Transaction Agreement, immediately prior to the Effective Time, the PRSUs, unless agreed otherwise, became fully vested, and at the Effective Time, were automatically converted into the right to receive an amount in cash (without interest and subject to all required withholding taxes) equal to the product of (i) the aggregate number of ADSs underlying such PRSU Award and (ii) the ADS Consideration.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 20, 2018 Filed Dec 21, 2018 17:11 UTC | Dova Pharmaceuticals Inc. DOVA · Entity 153784 | PurchaseCommon Stock | 10,000 | $6.07 | $60,700.00 |
DisclosureSEC source: 0001209191-18-063956 · doc4.xml · nonDerivative · entry 2 ZACCARDELLI DAVID · CIK 0001627642 · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,372 Read SEC document |
| December 19, 2018 Filed Dec 21, 2018 17:11 UTC | Dova Pharmaceuticals Inc. DOVA · Entity 153784 | GrantEmployee Stock Option (right to buy) · Derivative | 1,000,000 | $0.00 Strike: $6.07 | $0.00 |
DisclosureSEC source: 0001209191-18-063956 · doc4.xml · derivative · entry 3 ZACCARDELLI DAVID · CIK 0001627642 · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000,000 Underlying: Common Stock · 1,000,000 shares Expires 2028-12-18 F3 · derivative.exercise_date: 25% of the total shares subject to the option shall vest on December 17, 2019, and 1/48th of total shares subject to the option shall vest monthly thereafter over the remaining three years of the vesting period, subject to the Reporting Person's continuous service with the Issuer as of each such date. Read SEC document |
| December 19, 2018 Filed Dec 21, 2018 17:11 UTC | Dova Pharmaceuticals Inc. DOVA · Entity 153784 | GrantCommon Stock | 82,372 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-18-063956 · doc4.xml · nonDerivative · entry 1 ZACCARDELLI DAVID · CIK 0001627642 · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 82,372 F1 · shares: Represents a restricted stock unit ("RSU") award that vests 50% on June 28, 2019 and 25% on each of September 30, 2019 and December 31, 2019. F2 · price: Each RSU represents a contingent right to receive one share of Issuer common stock. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 20:54 UTC | MELINTA THERAPEUTICS, INC. /NEW/ MLNT · Entity 154249 | GrantStock Option (right to buy) · Derivative | 9,100 | $0.00 Strike: $7.45 | $0.00 |
DisclosureSEC source: 0000899243-18-016636 · doc4.xml · derivative · entry 2 ZACCARDELLI DAVID · CIK 0001627642 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,100 Underlying: Common Stock · 9,100 shares Expires 2028-04-20 F1 · date: The option grant was approved by the compensation committee of the Company's board of directors on April 20, 2018, subject to stockholder approval of an amendment to the stock option plan under which the option was granted. The Company's stockholders approved the plan amendment on June 12, 2018. Read SEC document |
| June 12, 2018 Filed Jun 14, 2018 20:54 UTC | MELINTA THERAPEUTICS, INC. /NEW/ MLNT · Entity 154249 | GrantStock Option (right to buy) · Derivative | 25,000 | $0.00 Strike: $7.45 | $0.00 |
DisclosureSEC source: 0000899243-18-016636 · doc4.xml · derivative · entry 1 ZACCARDELLI DAVID · CIK 0001627642 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2028-04-20 F1 · date: The option grant was approved by the compensation committee of the Company's board of directors on April 20, 2018, subject to stockholder approval of an amendment to the stock option plan under which the option was granted. The Company's stockholders approved the plan amendment on June 12, 2018. F2 · derivative.exercise_date: One-third of the shares underlying the stock option will vest and become exercisable on April 20, 2019. The remainder will vest and become exercisable in substantially equal monthly installments during the two year period commencing on April 20, 2019. Read SEC document |
| May 29, 2018 Filed May 31, 2018 21:14 UTC | MELINTA THERAPEUTICS, INC. /NEW/ MLNT · Entity 154249 | PurchaseCommon Stock | 40,000 | $5.00 | $200,000.00 |
DisclosureSEC source: 0000899243-18-014565 · doc4.xml · nonDerivative · entry 1 ZACCARDELLI DAVID · CIK 0001627642 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,500 F1 · kind: These shares were purchased from the underwriters pursuant to an underwritten public offering by the Issuer. The offering closed on May 29, 2018. F1 · price: These shares were purchased from the underwriters pursuant to an underwritten public offering by the Issuer. The offering closed on May 29, 2018. Read SEC document |
| December 09, 2016 Filed Dec 13, 2016 21:07 UTC | MELINTA THERAPEUTICS, INC. /NEW/ CEMP · Entity 154249 | GrantStock Option (Right to Buy) · Derivative | 150,000 | $0.00 Strike: $7.70 | $0.00 |
DisclosureSEC source: 0001209191-16-154889 · doc4.xml · derivative · entry 2 ZACCARDELLI DAVID · CIK 0001627642 · Director · Acting Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2026-12-09 F3 · derivative.exercise_date: The option vests on the following schedule: 1/12th of the shares vest monthly at the end of each month over 12 months, beginning after 12/09/2016, subject to continued employment or Board service. Read SEC document |
| December 09, 2016 Filed Dec 13, 2016 21:07 UTC | MELINTA THERAPEUTICS, INC. /NEW/ CEMP · Entity 154249 | GrantRestricted Stock Units · Derivative | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-154889 · doc4.xml · derivative · entry 1 ZACCARDELLI DAVID · CIK 0001627642 · Director · Acting Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Cempra, Inc. common stock. F2 · derivative.exercise_date: The restricted stock units vest in full on December 9, 2017, subject to continued employment or Board service. F2 · derivative.expiration_date: The restricted stock units vest in full on December 9, 2017, subject to continued employment or Board service. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.